Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P23470
UPID:
PTPRG_HUMAN
Alternative names:
-
Alternative UPACC:
P23470; B2RU12; B7ZLX5; Q15623; Q59EE0; Q68DU5
Background:
Receptor-type tyrosine-protein phosphatase gamma, encoded by the gene symbol P23470, plays a crucial role in cellular processes through its tyrosine phosphatase activity. This activity is pivotal in the modulation of tyrosine phosphorylation, a key post-translational modification that regulates various cellular pathways.
Therapeutic significance:
Understanding the role of Receptor-type tyrosine-protein phosphatase gamma could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways suggests its potential as a target in designing novel therapeutic interventions.